Transcarent launches bundled payment model for cancer therapies
The model offers members potential savings of up to $150,000, executives say.
Healthcare navigation platform Transcarent introduced a bundled payment model for cancer therapies on Tuesday, marking a first-of-its-kind initiative. The model supports bispecific T-cell engager (BiTE) and CAR T therapies, enabling Transcarent to connect its members to leading oncology providers across multiple settings, such as academic medical centers and high-quality community-based cancer care sites.
Transcarent president Snezana Mahon highlighted the challenges employers face in managing costs and access for advanced cancer therapies, stating that the new model provides more predictable costs and ensures members receive expert care close to home without compromising quality. This model enhances Transcarent's Centers of Excellence (COE) program, offering potential savings of up to $150,000, executives claim.
Additionally, members undergoing treatment through the COE network benefit from the support of certified oncology nurse navigators. Transcarent's Cancer Care Advisory Board Chair Karen Knudsen emphasized that expanding access to such therapies in high-quality community settings is crucial for more equitable cancer care. The new model aims to reduce barriers to treatment and improve the experience for individuals and their families dealing with some of the most complex cancers.
In January, Transcarent expanded its WayFinding platform with new agentic AI capabilities, including voice AI scheduling and advanced symptom-checking.
Written by urgent.news from Fierce Healthcare's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
